These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 10768512)

  • 1. A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study.
    Jessup C; Reyes G; Fothergill A; McCarthy D; Rinaldi M; Messer S; Pfaller M; Ghannoum M
    J Chemother; 2000 Feb; 12(1):22-9. PubMed ID: 10768512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P.
    Carrillo-Muñoz AJ; Ruesga M; Brio S; del Valle O; Rodriguez V; Santos P; Hernández-Molina JM; Cantón E; Pemán J; Guarro J; Quindós G
    Chemotherapy; 2002 Dec; 48(5):224-31. PubMed ID: 12476038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
    Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga M; Alonso R; del Valle O; Rodriguez V; Arévalo MP; Salgado J; Martin-Mazuelos E; Bornay-Llinares FJ; del Palacio A; Cuétara M; Gasser I; Hernández-Molina JM; Pemán J
    Chemotherapy; 2000; 46(4):235-44. PubMed ID: 10859429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.
    Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL
    J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of propyl gallate on the activity of various antifungal drugs against filamentous fungi in vitro].
    Xu Y; Pang GR; Lü XF; Chen ZJ; Sun ST; Song JZ
    Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):309-12. PubMed ID: 16762206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test.
    Ramani R; Chaturvedi V
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2752-8. PubMed ID: 10991856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
    Xu Y; Pang GR; Zhao DQ; Gao CW; Zhou LT; Sun ST; Wang BL; Chen ZJ
    Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):38-42. PubMed ID: 20388321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
    Isham N; Ghannoum MA
    J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.
    Herreros E; Martinez CM; Almela MJ; Marriott MS; De Las Heras FG; Gargallo-Viola D
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2863-9. PubMed ID: 9797217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Apr; 39(4):1360-7. PubMed ID: 11283057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
    Rudramurthy SM; Jatana M; Singh R; Chakrabarti A
    Mycoses; 2013 Jan; 56(1):39-46. PubMed ID: 22519679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
    Favel A; Michel-Nguyen A; Datry A; Challier S; Leclerc F; Chastin C; Fallague K; Regli P
    J Antimicrob Chemother; 2004 Mar; 53(3):526-9. PubMed ID: 14963064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
    Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
    J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.